The ASXL1 Knockout HT29 Polyclonal Cells represent a CRISPR/Cas9-edited polyclonal knockout cell population engineered for the disruption of the ASXL1 gene in the HT29 human colorectal adenocarcinoma cell line. This product provides a robust model for investigating the functional roles of Additional Sex Combs Like 1 (ASXL1) in solid tumor contexts, specifically within an intestinal epithelial background. The polyclonal nature of the knockout pool ensures genetic diversity, minimizing clonal artifacts while enabling reproducible loss-of-function studies.
HT29 cells are a well-characterized human colorectal adenocarcinoma epithelial line capable of spontaneous differentiation into enterocyte and goblet cell lineages under appropriate culture conditions. Originally isolated from a primary tumor, HT29 cells serve as an established model for intestinal biology, colorectal cancer progression, and differentiation studies. Their ability to form polarized monolayers and undergo glandular differentiation makes them particularly suitable for investigating epithelial-specific gene regulation and chromatin dynamics.
ASXL1 encodes a chromatin-binding protein that functions as a core component of the Polycomb repressive deubiquitinase (PR-DUB) complex, where it partners with the deubiquitinase BAP1 to catalyze the removal of monoubiquitin from histone H2A at lysine 119 (H2AK119ub1). ASXL1 directly interacts with BAP1, HCFC1, and OGT to form and stabilize the active PR-DUB complex, and its loss disrupts H2A deubiquitination, leading to hyperubiquitination of H2A. This dysregulation impairs Polycomb-mediated gene repression and genomic targeting of PR-DUB, thereby altering the expression of downstream transcriptional targets, including the HOXA gene cluster and genes governing myeloid differentiation. Consequently, ASXL1 is implicated in the epigenetic control of cellular identity and proliferation.
In the HT29 colorectal cancer context, knockout of ASXL1 provides a unique opportunity to dissect the PR-DUB complex’s role in intestinal epithelial homeostasis and transformation. Loss of ASXL1-mediated H2A deubiquitination is expected to perturb chromatin landscapes at loci critical for epithelial differentiation and tumor suppression, potentially recapitulating aspects of ASXL1 mutations observed in hematologic malignancies and Bohring-Opitz syndrome. The model thus bridges the gap between ASXL1’s well-documented role in myeloid disorders and its emerging significance in solid tumors, enabling studies on how epigenetic dysregulation drives colorectal cancer progression and modulates differentiation programs.
Researchers can employ these polyclonal knockout cells in a variety of assays to assess consequences of ASXL1 loss, including western blotting for H2A ubiquitination levels, RT-qPCR and RNA-seq for transcriptomic profiling of HOXA genes and other targets, ChIP-qPCR for histone modifications, and functional assays monitoring proliferation and differentiation under diverse conditions. The cells serve as a valuable platform for screening small-molecule epigenetic modulators or validating potential therapeutic targets that interact with the PR-DUB pathway. For additional technical details and support, please contact Ascent Research.
